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Background: The B cell survival factors B cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) can
heteromerize.
Results: BAFF-APRIL2 and APRIL-BAFF2 heteromers have distinct receptor-binding specificities and activities.
Conclusion: BAFF-APRIL2 resembles APRIL, and APRIL-BAFF2 resembles BAFF but poorly activates the BAFF receptor.
Significance:Heteromers should be taken into account when evaluating the physiology or pharmacological inhibition of BAFF
and APRIL.
The closely related TNF family ligands B cell activation factor
(BAFF) and a proliferation-inducing ligand (APRIL) serve in the
generation and maintenance of mature B-lymphocytes. Both
BAFF and APRIL assemble as homotrimers that bind and acti-
vate several receptors that theypartially share.However, hetero-
mers of BAFF and APRIL that occur in patients with autoim-
mune diseases are incompletely characterized. The N and C
termini of adjacent BAFF or APRIL monomers are spatially
close and can be linked to create single-chain homo- or hetero-
ligands of defined stoichiometry. Similar to APRIL, heteromers
consisting of one BAFF and two APRILs (BAA) bind to the
receptors B cell maturation antigen (BCMA), transmembrane
activator and CAML interactor (TACI) but not to the BAFF
receptor (BAFFR).Heteromers consisting of oneAPRIL and two
BAFF (ABB) bind to TACI and BCMA and weakly to BAFFR in
accordance with the analysis of the receptor interaction sites
in the crystallographic structure of ABB. Receptor binding
correlated with activity in reporter cell line assays specific
for BAFFR, TACI, or BCMA. Single-chain BAFF (BBB) and to
a lesser extent single-chain ABB, but not APRIL or single-
chain BAA, rescued BAFFR-dependent B cell maturation in
BAFF-deficient mice. In conclusion, BAFF-APRIL hetero-
mers of different stoichiometries have distinct receptor-
binding properties and activities. Based on the observation
that heteromers are less active than BAFF, we speculate that
their physiological role might be to down-regulate BAFF
activity.
BAFF,3 also known as BLyS (B lymphocyte stimulator), is a
TNF family ligand primarily expressed by myeloid cells and
radiation-resistant stromal cells of secondary lymphoid organs.
Together with its close relative APRIL, BAFF acts on peripheral
B cells at various stages of differentiation through three recep-
tors as follows: BAFFR that responds to BAFF only, and TACI
and BCMA that bind to both BAFF and APRIL (1). BAFFR
controls the survival andmetabolic fitness of peripheral B cells,
with the exception of memory cells, plasma cells, and B1 B cells
(2–4). BAFFR is highly expressed in naive B cells but decreases
and finally completely disappears during activation and differ-
entiation of B cells to plasma cells. In contrast, TACI is tran-
siently expressed in B cells upon activation, for example in
response to Toll-like receptor ligands (5). Its expression is par-
ticularly high in marginal zone B cells, but, as for BAFFR, it is
not maintained in plasma cells. The role of TACI is complex. It
is required for efficient antibody production in response to type
II T-independent antigens, but at the same time it exerts a neg-
ative role onB cells. Indeed, TACI-deficientmice display higher
numbers of B cells than their wild type counterparts (6, 7). In
marginal zone B cells, simultaneous engagement of TACI and
Toll-like receptors induces expression of both Fas and FasL to
help contract this innate-like type of response by apoptotic cell
death at a later stage (8). Finally, BCMA is expressed late during
B cell differentiation and is probably the prime receptor medi-
ating the action of BAFF and APRIL on plasma cells (2, 9). The
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blockade of BAFFwith amonoclonal antibody has proven to be
moderately effective in the autoimmune disease systemic lupus
erythematosus, and several other reagents blocking either
BAFF alone or BAFF and APRIL are presently in clinical devel-
opment (10).
BAFF exists in membrane-bound (11) or -soluble (12) forms,
and the latter can crystallize as 3- or 60-mers (13, 14). Although
APRIL is mainly released in a soluble form (15), it can bind to
proteoglycans and thus create niches for antibody-secreting
cells (16, 17). Heteromers of BAFF and APRIL are produced in
autoimmune diseases and are sometimes also detected in
healthy subjects (18, 19). Because of the intrinsic difficulty of
producing and purifying BAFF-APRIL heteromers, these
ligands have remained incompletely characterized. Here, we
produced single-chain heteromers of BAFF and APRIL with
defined compositions; we crystallized one of them and charac-
terized their receptor-binding profile, their activities, and their
susceptibility to BAFF or BAFF and APRIL inhibitors.
Experimental Procedures
Animals—C57BL/6 WT and BAFF-KO were as described
(20). Mice were handled according to guidelines and under the
authorization of the Swiss Federal Food Safety and Veterinary
Office (authorization 1370.6 to P. S.).
Plasmids and Recombinant Proteins—Expression plasmids
used in this study were constructed using standard molecular
biology techniques. Proteins they code for are described in
Table 1. Atacicept was provided by Merck, KGaA. Belimumab
(registered trade name Benlysta) was purchased from the Phar-
macy of LausanneUniversityHospital.Other recombinant pro-
teins were produced essentially as described (21, 22).
Transfections—HEK 293T cells were grown in DMEM, 10%
fetal calf serum(FCS) and transfectedby thecalciumphosphateor
polyethyleneimidemethods.Cellsweregrownfor7days in serum-
freeOpti-MEMmedium(Invitrogen) for theproductionof single-
chain lymphotoxins or for 48 h in complete medium for surface
expression of receptors:TRAILR3 fusion proteins.
CHO cells (Sigma) grown in DMEM/F-12 (1:1) supple-
mentedwith 2%FCSwere transfectedwith polyethylenimide or
Polyfect (Qiagen) and selected 48 h later in medium containing
500 g/ml G418 sulfate (Calbiochem). Cells were cloned by
limiting dilution or by two or three rounds of FACS sorting
when constructs of interest were linked to green fluorescent
protein expression via an internal ribosome entry site sequence.
The best producing clones were selected.
Protein Production and Purification—Conditioned superna-
tants were affinity-purified on anti-FLAGM2-agarose (Sigma)
or protein A-Sepharose (GE Healthcare) for FLAG- and
Fc-tagged ligands, respectively, essentially as described (21).
Single-chain ligands were subsequently fractionated by size
exclusion chromatography on a Superdex 200 column (GE
Healthcare) equilibrated in PBS. Protein concentrations were
inferred from the extinction coefficient calculated from the
theoretical amino acid sequence. Untagged single-chain het-
eromers were obtained by secretion from HEK 293 cells with
N-terminal His6-FLAG tags, affinity chromatography on nick-
el-nitrilotriacetic acid, tag cleavagewith tobacco etch virus pro-
tease, and size exclusion chromatography on a Superdex 200
column. The final purified proteins were prepared in 20 mM
Hepes/NaOH, pH 7.5, 150 mMNaCl and were concentrated on
30-kDa ultrafiltration devices (Vivascience).
SDS-PAGE andWestern Blot—SDS-PAGE andWestern blot
were performed according to standard procedures. Proteins
were revealed directly with horseradish peroxidase-coupled
anti-human IgG antibody or in two stepswith anti-FLAGM2 at
1 g/ml, anti-hBAFF Buffy-2 rat IgM at 1 g/ml, or anti-
hAPRILAprily-2mouse IgG1 at 1g/ml, followed by appropri-
ate horseradish peroxidase-coupled secondary reagents. Coo-
massie blue staining was performed with a semidry iD Stain
System (Eurogentec).
Receptor-Ligand Interaction ELISA—The direct binding of
FLAG-tagged ligands to immobilized receptor-Fcs, either
adsorbed to or captured via anti-human antibodies in 96-well
immunoplates, was revealed with biotinylated anti-FLAG M2
antibody (Sigma) and horseradish-coupled streptavidin as
described previously in detail (22). For the competition ELISA,
titrated amounts of untagged ligands were added to immobi-
lized receptor-Fcs for 30 min and followed, without intermedi-
ate washing step, by an empirically determined fixed and non-
saturating concentration of FLAG-tagged ligand sufficient to
generate80% of themaximal signal in the absence of compet-
itor (22).
Cytotoxic Assays with Receptor:Fas Reporter Cell Lines—Jur-
kat BCMA:Fas (cl13) and Jurkat JOM2TACI:Fas (cl112.3) have
been described (20, 23). Similarly, Jurkat JOM2 BAFFR:Fas cell
lines (cl21) were generated as described in detail elsewhere by
retrovirus-mediated transduction of a BAFFR:Fas chimeric
receptor, puromycin selection, and screening of clones for their
selective ability to respond to Fc-BAFF by apoptotic cell death
(22). Reporter cells were incubated for 16 h with the indicated
concentrations of ligands, after which time cell viability was
measured by the phenazine methosulfate/3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium assay essentially as described (22). FLAG-
tagged ligands were used in the presence of 1g/ml anti-FLAG
M2 antibody.
Crystallography—Crystals of the single-chain APRIL-BAFF-
BAFF heterotrimer (His6-FLAG-TEV-GS-hAPRIL (aa 111–
250, T126A)-GGGGS-hBAFF(140–285)-GGGGS-hBAFF(140–
285), with cleaved tags) were obtained by mixing 0.5 l of
protein solution (6 mg/ml in 20 mM Hepes/NaOH, pH 7.5, 150
mMNaCl) with 0.5 l of reservoir solution (0.1 M Tris/HCl, pH
8.75, 14% PEG6000 (w/v), and 1 M LiCl) using the hanging drop
vapor diffusionmethod at 293 K. Before flash-freezing in liquid
nitrogen, crystals were cryo-protected by reservoir solution
supplemented with 10% (v/v) 2,3-butanediol.
Diffraction data were collected at 100 K at beamline X06SA
(Swiss Light Source, Villigen, Switzerland). Data were pro-
cessed to 2.43 Å resolution using the programs XDS and
XSCALE (24). The crystals belong to space group C 2 2 21
containing two heterotrimers per asymmetric unit. Initial
phases were obtained by molecular replacement using Phaser
and the published structures of APRIL (ProteinData Bank code
1Q5X) and BAFF (Protein Data Bank code 1KD7) as search
models (25). Multiple rounds of manual model building in
COOT and bulk solvent correction, positional, B-factor, and
Single-chain BAFF-APRIL Heteromers
JUNE 26, 2015•VOLUME 290•NUMBER 26 JOURNAL OF BIOLOGICAL CHEMISTRY 16331
 at U
niversité de Lausanne on February 21, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
T
A
B
LE
1
P
la
sm
id
s
u
se
d
in
th
is
st
u
d
y
aa
is
am
in
o
ac
id
.H
A
sig
na
l
M
AI
IY
LI
LL
FT
AV
RG
Ig
sig
na
l
M
N
FG
FS
LI
FL
VL
VL
KG
Ca
m
Li
nk
er

PQ
PQ
PK
PQ
PK
PE
PE
G
S
Pr
eS
ci

LE
VL
FQ
G
P
TE
V

EN
LY
FQ
.
Pl
as
m
id
De
sig
na
tio
n
Pr
ot
ein
en
co
de
d
Ve
ct
or
ps
19
3
FL
AG
-h
TN
F
H
A
sig
na
l-F
LA
G
-G
PG
Q
VQ
LQ
-h
TN
F
(a
a8
5–
26
3)
PC
R3
ps
42
0
hT
N
FR
1-
Fc
hT
N
FR
1(
aa
1–
21
7)
-V
D-
hI
gG
1(
aa
24
5–
47
0)
PC
R3
ps
51
5
EG
FP
En
ha
nc
ed
gr
ee
n
flu
or
es
ce
nt
pr
ot
ein
PC
R3
ps
64
5
FL
AG
-h
LT
a
H
A
sig
na
l-F
LA
G
-G
PG
Q
VQ
LQ
VD
-h
TN
F
(a
a4
3–
20
5)
PC
R3
ps
73
9
hB
CM
A-
Fc
Ig
sig
na
l-E
VK
LV
PR
G
S-
hB
CM
A
(a
a2
–5
4)
-V
D-
hI
gG
1(
aa
24
5–
47
0)
PC
R3
ps
89
7
hT
AC
I-G
PI
H
A
sig
na
l-L
D-
hT
AC
I(
aa
2–
16
0)
-V
D-
hT
RA
IL
R3
(a
a1
57
–2
69
)
PC
R3
ps
11
96
Fc
-h
BA
FF
H
A
sig
na
l-L
D-
hI
gG
1(
aa
24
5–
47
0)
-R
S-
Ca
m
Li
nk
er
-P
re
Sc
i-G
SL
Q
-h
BA
FF
(a
a1
37
–2
85
)
PC
R3
ps
13
77
pM
SC
V-
pu
ro
M
od
ifi
ed
pM
SC
V-
pu
ro
(
zc
o;
clo
nt
ec
h
Cl
on
te
ch
)w
ith
H
in
dI
II-
Bg
lII
-E
co
RI
-N
ot
I-X
ho
I-H
pa
I-A
pa
Ic
lo
ni
ng
sit
es
ps
13
77
ps
14
06
Fc
-h
LT
b
H
A
sig
na
l-L
D-
hI
gG
1(
aa
24
5–
47
0)
-R
S-
Ca
m
Li
nk
er
-P
re
Sc
i-G
SL
Q
-h
LT
b
(a
a6
6–
24
4)
PC
R3
ps
14
67
hB
CM
A-
G
PI
Ig
sig
na
l-V
Q
CE
VK
LV
PR
G
S-
hB
CM
A
(a
a2
–5
4)
-V
D-
hT
RA
IL
R3
(a
a1
57
–2
69
)
PC
R3
ps
15
89
hB
AF
FR
-G
PI
H
A
sig
na
l-L
E-
hB
AF
FR
(a
a2
–7
1)
-E
FG
SV
D-
hT
RA
IL
R3
(a
a1
57
–2
69
)
PC
R3
ps
17
99
m
LT
bR
-F
c
m
LT
bR
(a
a1
–2
20
)-V
D-
Pr
eS
ci-
hI
gG
1(
aa
24
5–
47
0)
PC
R3
ps
22
97
m
BA
FF
R-
Fc
H
A
sig
na
l-L
D-
m
BA
FF
R
(a
a2
–7
0)
-V
D-
hI
gG
1(
aa
24
5–
47
0)
PC
R3
ps
23
08
hB
AF
FR
:F
as
H
A
sig
na
l-L
E-
hB
AF
FR
(a
a2
–7
1)
-E
FG
SV
D-
hF
as
(a
a1
69
–3
55
)
ps
13
77
ps
23
09
hB
CM
A:
Fa
s
Ig
sig
na
l-V
Q
CE
VK
LV
PR
G
S-
hB
CM
A
(a
a2
–5
4)
-V
D-
hF
as
(a
a1
69
–3
35
)
ps
13
77
ps
24
55
hT
AC
I:F
as
H
A
sig
na
l-L
-h
TA
CI
(a
a1
–1
18
)-V
D-
hF
as
(a
a1
69
–3
35
)
ps
13
77
ps
26
42
FL
AG
-h
LT
-


H
A
sig
na
l-F
LA
G
-G
PG
Q
VQ
LQ
VD
-h
LT
a(
aa
58
–2
05
)-G
G
G
G
S-
hL
Ta
(a
a5
8–
20
5)
-G
G
G
G
S-
hL
Ta
(a
a5
8–
20
5)
PC
R3
ps
26
43
FL
AG
-h
LT
-


H
A
sig
na
l-F
LA
G
-G
PG
Q
VQ
LQ
VD
-h
LT
a(
aa
58
–2
05
)-G
G
G
G
S-
hL
Ta
(a
a5
8–
20
5)
-G
G
G
G
S-
hL
Tb
(a
a8
3–
24
4)
PC
R3
ps
26
44
FL
AG
-h
LT
-


H
A
sig
na
l-F
LA
G
-G
PG
Q
VQ
LQ
-h
LT
b
(a
a8
3–
24
4)
-G
G
G
G
S-
hL
Ta
hL
Tb
(a
a8
3–
24
4)
-G
G
G
G
S-
hL
Ta
(a
a5
8–
20
5)
PC
R3
ps
26
45
FL
AG
-h
LT
-


H
A
sig
na
l-F
LA
G
-G
PG
Q
VQ
LQ
-h
LT
b
(a
a8
3–
24
4)
-G
G
G
G
S-
hL
Ta
hL
Tb
(a
a8
3–
24
4)
-G
G
G
G
S-
hL
Tb
(a
a8
3–
24
4)
PC
R3
ps
26
80
Fc
-B
BB
H
A
sig
na
l-L
D-
hI
gG
1(
aa
24
5–
47
0)
-R
S-
Ca
m
Li
nk
er
-L
Q
-h
BA
FF
(a
a1
40
–2
85
)-G
G
G
G
S-
hB
AF
F
(a
a1
40
–2
85
)-G
G
G
G
S-
hB
AF
F
(a
a1
40
–2
85
)
PC
R3
ps
28
26
Fc
-h
AP
RI
L
H
A
sig
na
l-L
D-
hI
gG
1(
aa
24
5–
47
0)
-R
S-
Ca
m
Li
nk
er
-G
SL
Q
-h
AP
RI
L
(a
a1
15
–2
50
)
PC
R3
ps
28
76
Fc
-A
AA
H
A
sig
na
l-L
D-
hI
gG
1(
aa
24
5–
47
0)
-R
S-
Ca
m
Li
nk
er
-L
Q
-h
AP
RI
L
(a
a1
12
–2
50
)-G
G
G
G
S-
hA
PR
IL
(a
a1
12
–2
50
)-G
G
G
G
S-
hA
PR
IL
(a
a1
12
–2
50
)I
RE
S
G
FP
PC
R3
ps
28
77
Fc
-B
AA
H
A
sig
na
l-L
D-
hI
gG
1(
aa
24
5–
47
0)
-R
S-
Ca
m
Li
nk
er
-L
Q
-h
BA
FF
(a
a1
40
–2
85
)-G
G
G
G
S-
hA
PR
IL
(a
a1
12
–2
50
)-G
G
G
G
S-
hA
PR
IL
(a
a1
12
–2
50
)I
RE
S
G
FP
PC
R3
ps
28
79
FL
AG
-A
AA
H
A
sig
na
l-F
LA
G
-G
PG
Q
VQ
LQ
-h
AP
RI
L
(a
a1
12
–2
50
)-G
G
G
G
S-
hA
PR
IL
(a
a1
12
–2
50
)-G
G
G
G
S-
hA
PR
IL
(a
a1
12
–2
50
)I
RE
S
G
FP
PC
R3
ps
28
83
Fc
-A
BB
H
A
sig
na
l-L
D-
hI
gG
1(
aa
24
5–
47
0)
-R
S-
Ca
m
Li
nk
er
-L
Q
-h
AP
RI
L
(a
a1
12
–2
50
)-G
G
G
G
S-
hB
AF
F
(a
a1
40
–2
85
)-G
G
G
G
S-
hB
AF
F
(a
a1
40
–2
85
)I
RE
S
G
FP
PC
R3
ps
28
86
FL
AG
-A
BB
H
A
sig
na
l-F
LA
G
-G
PG
Q
VQ
LQ
-h
AP
RI
L
(a
a1
12
–2
50
)-G
G
G
G
S-
hB
AF
F
(a
a1
40
–2
85
)-G
G
G
G
S-
hB
AF
F
(a
a1
40
–2
85
)I
RE
S
G
FP
PC
R3
ps
28
89
FL
AG
-B
AA
H
A
sig
na
l-F
LA
G
-G
PG
Q
VQ
LQ
-h
BA
FF
(a
a1
40
–2
85
)-G
G
G
G
S-
hA
PR
IL
(a
a1
12
–2
50
)-G
G
G
G
S-
hA
PR
IL
(a
a1
12
–2
50
)I
RE
S
G
FP
PC
R3
ps
28
90
FL
AG
-B
BB
H
A
sig
na
l-F
LA
G
-G
PG
Q
VQ
LQ
-h
BA
FF
(a
a1
40
–2
85
)-G
G
G
G
S-
hB
AF
F
(a
a1
40
–2
85
)-G
G
G
G
S-
hB
AF
F
(a
a1
40
–2
85
)I
RE
S
G
FP
PC
R3
ps
34
13
hT
AC
I-F
c
M
od
ifi
ed
Ig
sig
na
l(
M
ET
DT
LL
LW
VL
LL
W
VP
G
VH
G
)-h
TA
CI
(a
a3
1–
11
0)
hI
gG
1(
aa
24
5–
47
0;
L2
58
E,
A3
53
S,
P3
54
S)
PC
R3
pc
DN
A3
.1_
AA
B
AA
B
Ig
sig
na
l-H
is6
-F
LA
G
-T
EV
-G
S-
hA
PR
IL
(a
a1
11
–2
50
;T
12
6A
)-G
G
G
G
S-
hA
PR
IL
(a
a1
11
–2
50
;T
12
6A
)-G
G
G
G
S-
hB
AF
F
(a
a1
40
–2
85
)
pc
DN
A3
.1
pc
DN
A3
.1_
AB
A
AB
A
Ig
sig
na
l-H
is6
-F
LA
G
-T
EV
-G
S-
hA
PR
IL
(a
a1
11
–2
50
;T
12
6A
)-G
G
G
G
S-
hB
AF
F
(a
a1
40
–2
85
)-G
G
G
G
S-
hA
PR
IL
(a
a1
11
–2
50
;T
12
6A
)
pc
DN
A3
.1
pc
DN
A3
.1_
BA
A
BA
A
Ig
sig
na
l-H
is6
-F
LA
G
-T
EV
-G
S-
hB
AF
F
(a
a1
40
–2
85
)-G
G
G
G
S-
hA
PR
IL
(a
a1
11
–2
50
;T
12
6A
)-G
G
G
G
S-
hA
PR
IL
(a
a1
11
–2
50
;T
12
6A
)
pc
DN
A3
.1
pc
DN
A3
.1_
BB
A
BB
A
Ig
sig
na
l-H
is6
-F
LA
G
-T
EV
-G
S-
hB
AF
F
(a
a1
40
–2
85
)-G
G
G
G
S-
hB
AF
F
(a
a1
40
–2
85
)-G
G
G
G
S-
hA
PR
IL
(a
a1
11
–2
50
;T
12
6A
)
pc
DN
A3
.1
pc
DN
A3
.1_
BA
B
BA
B
Ig
sig
na
l-H
is6
-F
LA
G
-T
EV
-G
S-
hB
AF
F
(a
a1
40
–2
85
)-G
G
G
G
S-
hA
PR
IL
(a
a1
11
–2
50
;T
12
6A
)-G
G
G
G
S-
hB
AF
F
(a
a1
40
–2
85
)
pc
DN
A3
.1
pc
DN
A3
.1_
AB
B
AB
B
Ig
sig
na
l-H
is6
-F
LA
G
-T
EV
-G
S-
hA
PR
IL
(a
a1
11
–2
50
;T
12
6A
)-G
G
G
G
S-
hB
AF
F
(a
a1
40
–2
85
)-G
G
G
G
S-
hB
AF
F
(a
a1
40
–2
85
)
pc
DN
A3
.1
Single-chain BAFF-APRIL Heteromers
16332 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290•NUMBER 26•JUNE 26, 2015
 at U
niversité de Lausanne on February 21, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
TLS refinement using REFMAC and BUSTER yielded the final
model (26–29). Data collection and model statistics are shown
in Table 2. The atomic coordinates and structure factors have
been deposited in the Protein Data Bank, Protein Data Bank
code 4ZCH. Images were generated with the PyMOL Molecu-
lar Graphics System, Schro¨dinger, LLC.
Administration of Proteins to BAFF-deficient and Wild Type
Animals—Fc-BBB, Fc-ABB, Fc-BAA, Fc-APRIL, and PBS were
administered intraperitoneally to BAFF-KOmice at 1mg/kg on
days 0, 4, 7, 11, and 14. Untreated wild type mice were used as
controls. Mice were sacrificed at day 18, and spleens and lymph
nodes (inguinal, axillary, and brachial) were collected, homog-
enized, incubated in ACK lysis buffer (150 mM NH4Cl, 10 mM
KHCO3, 10 M Na2-EDTA) for 5 min on ice to lyse red blood
cells, washed in PBS 2% FCS, and filtered on a nylon mesh.
FACS Analyses—293T cells co-transfected with EGFP and
receptor-GPI expression plasmids were stained with titrated
amounts of FLAG- or Fc-tagged ligands, whose binding was
revealedwithappropriatephycoerythrin-coupled secondary re-
agents, as described (22, 30). Cells were analyzed using
FACScan or Accuri 6 flow cytometers (BD Biosciences) and
FlowJo software (TreeStar, Ashland, OR).
Splenocytes or lymph node cells were incubated with anti-
CD16/32 (Fc-block, clone 93) and stained with a mix of
anti-CD19-PE.Cy7 (clone eBio1D3, 1:200), anti-CD93-biot
(mAb493, 1:100, a kind gift of Antonius Rolink, University of
Basel, Switzerland), and anti-CD3-APC (clone 17A2, 1:100) (all
from eBiosciences) for 20min on ice followed by phycoerythrin
Cy5.5-coupled streptavidin (1:100) and analysis with a FACS
Canto (BD Biosciences). Data were analyzed with the FlowJo
software.
Results
Production of Functional Single-chain Heteromers of LT
and - with Defined Stoichiometry—TNF family members
share a common structural fold, the TNF homology domain,
that trimerizes to form receptor-binding sites at the interface of
ligand subunits. In the structure of TNF and of several other
TNF family ligands, the N- and C-terminal regions of mono-
meric ligand subunits are only 5–11 Å away from each other
(14, 31, 32), making it possible to link three individual mono-
merswithin a trimer by replacing the Stop codon of the first and
secondmonomers by short linker peptides (sequence GGGGS)
to produce single-chain ligands (Fig. 1A). TNF is known to
remain active as a single-chain ligand (33). We first validated
the single-chain ligand approach using lymphotoxin- and -
(LT and LT). LT and LT form both homo- and hetero-
trimers of physiologic relevance that differ in their receptor-
binding profile: LT binds to TNFR1 and LT12 binds to
LTR (34).Moreover, single-chain LT12 remains active (35).
Single-chain FLAG-tagged constructs expressing LT and
LT in various combinations (, , , and , theo-
retical molecular weight of 51.5, 52.4, 53.0, and 53.9) were all
successfully expressed and secreted by 293T cells (Fig. 1B).
Conventional FLAG-TNF, FLAG-LT, or FLAG-LT co-ex-
pressed with Fc-LT were used as controls. As expected,
FLAG-TNF and FLAG-LT bound TNFR1, but not LTR, in
an ELISA-based assay, and the same was true for single-chain
LT-LT-LT (Fig. 1C). LT-, the bona fide ligand for
LTR, and single-chain LT-LT-LT bound to LTR but not
to TNFR1, whereas single-chain LT-LT-LT showed an
intermediate specificity with some binding to both TNFR1 and
LTR (Fig. 1C). Taken together, these results indicate that both
LT and LT retain the ability to interact with cognate recep-
tors when modified at their C termini and expressed as single-
chain ligands. The observation that LT- did not bind to
TNFR1 strongly suggests that, as expected, the stoichiometry is
fixed in single-chain ligands. Indeed, if  subunits from differ-
ent single-chain heteromers had the capacity to assemble into
TABLE 2
Crystallographic data andmodel refinement statistics
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pure LT trimers, binding to TNFR1 should have been
detected, which was not the case.
Expression and Purification of Single-chain BAFF, APRIL,
and BAFF-APRIL Heteromers—Affinity-purified FLAG- and
Fc-tagged single-chain ligands produced inCHOcellsmigrated
by SDS-PAGE with sizes of about 60 and 100 kDa, respectively,
corresponding roughly to the predicted molecular masses of
the glycosylated proteins (Fig. 2A and Table 3). AWestern blot
analysis confirmed the presence of both BAFF andAPRIL in the
single-chain heteromers and of either BAFF or APRIL in the
homomers (Fig. 2A). Despite several expression attempts, sin-
gle-chainAPRILwas only obtained in low yield, especiallywhen
Fc-tagged.
FLAG-tagged ligands were eluted by size exclusion chroma-
tography with apparent molecular masses 1.5–1.7-fold higher
than the expected ones (Table 3). We find it unlikely that these
molecules assemble as dimers and favor the hypothesis that the
proteins have either nonglobular shapes and/or that the contri-
bution of N-linked glycans to the hydrodynamic volume is
higher than anticipated.
Fc-tagged single-chain ligands migrated by size exclusion
chromatography with apparent sizes 2.8 to 5 times that of the
monomeric single chain (Table 3), although in theory, given the
dimeric nature of the Fc, it should have been only twice the size.
Sizes of nonglobular proteins are overestimated by size exclu-
sion chromatography, and we hypothesize that the presence of
rod-like linkers (PQPQPKPQPKPEPEGS) between the Fc por-
tion and the single-chain ligands might have contributed to the
observed migration. Fc-tagged ABB and BBB were bigger by
size exclusion chromatography than Fc-tagged BAA and AAA,
and they might represent structures composed of four single
chains (i.e. containing two dimeric Fc). When present, aggre-
gates eluting in the void volume had been analyzed separately
and share the same receptor-binding properties as nonaggre-
gated ligands (data not shown).
Single-chain heteromers of BAFF and APRIL constructed in
six possible combinations (AAB, ABA, BAA, ABB, BAB, and
BBA)were also produced as untagged proteins inHEK 293 cells
(Fig. 2B). In these constructs, oneN-glycosylation site of APRIL
was mutated (T126A). These proteins migrated by SDS-PAGE
and size exclusion chromatography with sizes compatible with
the theoretical ones (Fig. 2B and Table 3).
Taken together, these results indicate that single-chain
homomers and heteromers of BAFF and APRIL can be pro-
duced but for single-chain APRIL only in low yield. All experi-
ments were performed with size-fractionated ligands to
exclude contributions of high molecular weight aggregates.
Crystal Structure of Single-chain APRIL-BAFF-BAFF Het-
eromer—The structure of untagged single-chain ABB deter-
mined by crystallography at a resolution of 2.43 Å revealed the
expected trimeric arrangement between theAPRIL and the two
BAFF subunits (Fig. 3, A and B). Interfaces between BAFF and
APRIL involve residues that are mostly identical or conserved
between both ligands, with conserved residues present at the
core of the interaction surface, explaining why heteromeriza-
FIGURE1.Receptor-bindingspecificityof lymphotoxin-heteromersof
defined stoichiometries. A, schematic representation of “conventional”
(FLAG LT) and single-chain ligands (FLAG single-chain LT-LT-LT, FLAG
LT-) in which individual monomers are covalently linked by a flexible
linker of five amino acid residues. B, anti-FLAGWestern blot (WB) of the indi-
cated single-chain FLAG-tagged lymphotoxins. C, binding of the indicated
FLAG-tagged conventional or single-chain ligands to immobilized TNFR1-Fc
(upper panel) or LTR-Fc (lower panel), as measured in an ELISA-based assay.
LT/Fc-LT is FLAG-LT co-expressed with Fc-LT.
FIGURE 2. SDS-PAGE analysis of single-chain BAFF-APRIL heteromers. A,
Western blot analysis with 200 ng/lane of FLAG-tagged or 100 ng/lane of
Fc-tagged single-chain BAFF-APRIL heteromers (except for Fc-AAA,20 ng)
revealed as indicated with either anti-BAFF Buffy-2, anti-FLAGM2, anti-APRIL
Aprily-2 monoclonal antibodies, or with an anti-Fc antibody. B, Coomassie
Blue staining of 6 g/lane (except for AAB, 1 g) of the indicated untagged
single-chain BAFF-APRIL heteromers.WB, Western blot.
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tion can take place (Fig. 3C). Subunits of BAFF monomers
adopt a folding very similar to that of BAFF previously crystal-
lized as 3- or 60-mers (r.m.s.d. of 0.47 to 0.54 Å) (Fig. 3D) (13,
14, 36–38), and the same was true for the APRIL subunit that
resembled previously crystallized mouse APRIL (r.m.s.d. of
1.56 or 0.76 Å when excluding loop EF that is different in both
structures) (Fig. 3F) (32). In particular, the N and C termini of
BAFF and APRIL in the heteromer superimposed with those of
conventional BAFF and APRIL, indicating that GGGGS linkers
between BAFF and APRIL subunits have no noticeable impact
on the structure (Fig. 3,D–F). Except for a single glycine residue
at the C terminus of the central BAFF subunit, linkers were
flexible and unresolved in the structure. It is noteworthy that
BAFF subunits at the C termini of bothABBs in the asymmetric
TABLE 3
Sizes of single-chain constructs of BAFF and APRIL
Constructsa
Theoretical no.
of N-linkedb
Theoretical approximate
mass (N-linked)c
Observed approximate
mass, WB DTT
Observed approximate
mass, S200
Ratio,
S200/WB
kDa kDa kDa
FLAG-AAA 6 64.3 58 85 1.5
FLAG-BAA 5 62.5 60 90 1.5
FLAG-ABB 4 60.9 59 100 1.7
FLAG-BBB 3 59.3 58 95 1.6
Fc-AAA 7 92.7 98 270 2.8
Fc-BAA 6 91 98 330 3.4
Fc-ABB 5 89.4 93 500 5.4
Fc-BBB 4 88 100 500 5.0
BAA, ABA, AAB 3 56.1 51d 40 0.8
ABB, ABA, BBA 3 56.8 54e 45 0.8
a Tagged constructs were produced in CHO cells, and untagged constructs were produced in HEK 293 cells.
b Number of consensus N-glycosylation sites (NX(S/T)) is shown.
c We assume that all consensus sites are glycosylated and counted 2.5 kDa per N-linked glycan.
d 51- and 54-kDa bands were observed and are probably N-glycosylation species.
e 51-, 54-, and 57-kDa bands were observed and are probably N-glycosylation species.
FIGURE 3. Structural features of an APRIL-BAFF-BAFF heteromer. A, top view of a single-chain APRIL-BAFF-BAFF heteromer, with APRIL in magenta, and
both BAFFs (BAFF2 and BAFF3) in blue and cyan. Ribbon drawing of the structure, in a semi-transparent space-filling representation. B, side view of the
APRIL-BAFF-BAFFheteromerwith the samecolor codeas inA.C, residues that are involved inprotomer interactions and that are conserved in the five interfaces
examined (BAFF-BAFF in 1OQE, APRIL-APRIL in 1XU1, BAFF3-BAFF2, APRIL1-BAFF3, and BAFF2-APRIL1 in ABB) are shown in red. Other residues of BAFF (wheat)
or APRIL (light pink) that participate in protomer-protomer interactions are also shown. Portions of the relevant -sheets of BAFF are shown in pale blue
(-sheets of APRIL, not shown, are essentially superimposable). The two protomers were rotated by about 90° and90°, respectively, so that both sides of the
interaction surface face the reader. D, ribbon representation of superimposed monomers of BAFF taken from structures of BAFF 3-mers (shades of light blue,
1KD7 and 1KXG), BAFF 60-mers (shades of gray, 1ODQ, 1OQE, and 4V46), and ABB heteromer (second BAFF domain, dark blue; third BAFF domain, shades of
cyan, as found in the two heteromers of the crystallization unit). The position of the DE loop (Flap) and of the N and C termini are indicated. E, two BAFF
protomers (light shades of blue) and one BAFFR molecule (orange) taken from the crystal structure of BAFF 60-mer in complex with BAFFR (1OQE) were
superimposedwith the two adjacent BAFF domains (in dark shadesof blue) of single-chain ABB. The side chains of Arg-30 of BAFFR andAsp-275 of BAFF,which
are both determinants of BAFFR specificity for BAFF and not APRIL, are shown in green and red, respectively. The electrostatic potential of the relevant portion
of theBAFF-BAFF interface in theheteromer is shown in the inset, from red (negative) toblue (positive). F, relevant ligand subunits of BAFF (1OQE), APRIL (1XU1),
and single-chain ABB were superimposed. APRIL and BAFF subunits of the ABB heteromer are shown in dark shades of magenta and blue, respectively. One
BAFF subunit (light blue) and one BAFFR (orange) of the BAFF-BAFFR complex (1OQE) are also shown, together with a relevant subunit of mouse APRIL (pink)
of the APRIL-TACI complex (1XU1). N and C termini are indicated. Side chains of Arg-30 of BAFFR and His-241 of APRIL are shown in green. The electrostatic
potential of the APRIL-BAFF interface is shown in the inset.
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unit of the crystal displayed a striking structural difference in
the “flap” region, i.e. the loop between-sheetsD andE (r.m.s.d.
of 2.25 Å between BAFF2 and BAFF3, but only 0.4 Å when
excluding the DE loop). In these BAFF subunits, the flap adopts
a different but well structured conformation in which the DE
-pleated sheet is longer, and the loop is reduced in size (Fig.
3D).
The receptor binding regions of the heteromer were exam-
ined for their predicted ability to accommodate BAFFR. Most
TNF family receptors have elongated extracellular domains
that contact ligands at the interface of two adjacent ligand
protomers (39, 40). In contrast, BAFFRmainly contacts a single
BAFF protomer (36, 37). Arg-30 of BAFFR, a known determi-
nant of its specificity for BAFF and not APRIL (41), is also con-
tacted by Asp-275 of the adjacent BAFF protomer (Fig. 3E).
APRIL has a histidine at the corresponding position (His-241),
and compared with the BAFF-BAFF interface, the APRIL-
BAFF interface more generally lacks the negatively charged
microenvironment that accommodates Arg-30 of BAFFR (Fig.
3F). Thus, ABB may present only one high affinity site for
BAFFR instead of three in BBB, which would result in a
decreased avidity for BAFFR.
In summary the crystal structure of single-chain ABB indi-
cates the following: (i) linkers do not interfere with folding and
assembly of BAFF and APRIL subunits; (ii) the structure of
human and mouse APRIL monomers are very similar; (iii) the
flap of the C-terminal BAFF subunit of ABB adopts a structure
that has never been observed before; and (iv) ABB is predicted
to bind BAFFR with a lower avidity than BAFF.
Receptor Binding Specificity of Single-chain BAFF, APRIL,
and BAFF-APRIL Heteromers—The binding of FLAG-tagged
single-chain ligands to immobilized BAFFR-Fc, BCMA-Fc, and
TACI-Fc was characterized in an ELISA-based assay. FLAG-
BBB bound BAFFR, BCMA, and TACI but not the irrelevant
TNFR1, and FLAG-AAA only bound BCMA and TACI, as
observed previously for conventional ligands. For heteromers,
FLAG-BAA behaved like AAA. FLAG-ABB bound all three
receptors, but its binding to BAFFR, and to a lesser extent
TACI,was clearly less efficient than that of BBB (Fig. 4A). In line
with these results, untagged heteromers were unable to com-
pete for FLAG-BAFF binding to BAFFR, indicating that the
binding affinity of ABB (and BAB and BBA) for BAFFR is lower
than that of BAFF (Fig. 4B). In contrast, all heteromers could
compete with FLAG-BAFF binding to BCMA, indicating that
BAFF and BAFF-APRIL heteromers have similar affinities for
BCMA (Fig. 4B).
The receptor-binding specificity of FLAG-tagged hetero-
mers was also tested in a FACS-based assay, in which GPI-
anchored receptors were expressed in 293T cells (Fig. 4C) (30).
Binding results were virtually identical to those of the ELISA-
based assay (Fig. 4D). Taken together, these data indicate that
BAA is close to APRIL in terms of receptor binding and that
ABB in addition displays some binding to BAFFR, but not to the
same level as BAFF.
Activity of Single-chain BAFF, APRIL, and BAFF-APRIL Het-
eromers on Reporter Cells—FLAG-tagged single-chain ligands
were tested for their ability to induce death in apopto-
sis-sensitive Jurkat T cells expressing the extracellular domains
of BAFFR, BCMA, or TACI fused to the transmembrane
domain and intracellular tail of the death-inducing receptor
Fas. Thus, successful binding and oligomerization of the recep-
tor:Fas fusion proteins by BAFF or APRIL induces death of
target cells through the surrogate Fas pathway. As triggering of
the Fas pathway is intimately linked to the multimerization
state of ligands (42), FLAG-tagged single-chain ligands were
incubated in the presence of a cross-linking anti-FLAG anti-
body. All ligands killed TACI:Fas cells and BCMA:Fas cells,
although AAA and to a lesser extent BAA were more active
thanABB and BBB on BCMA:Fas cells. On BAFFR:Fas reporter
cells, BBB was about 300-fold more efficient than ABB, in line
with the poor binding of ABB to BAFFR (Figs. 4 and 5A). As
expected from binding data, BAA and AAA have virtually no
activity on BAFFR:Fas cells (Fig. 5A). Similar results were
obtained for Fc-tagged single-chain ligands, except that differ-
ences between ligands were less marked than with FLAG-
tagged ligands when assayed on TACI:Fas reporter cells (Fig.
5B). Whether this was due to an increased avidity of dimeric Fc
ligands for TACI or to differences in protein preparation or
assay conditions is not known. Finally, untagged single-chain
ligands displayed activities mostly in line with those of the cor-
responding FLAG-tagged proteins, and there were no major
differences between heterotrimers in which subunits of identi-
cal composition were present in a different order (Fig. 5C).
Taken together, these results indicate that the activity of single-
chain ligands on receptor:Fas cells reflects quite precisely their
receptor binding ability and that the order in which BAFF and
APRIL subunits are fused within a single-chain heteromer
appears to be indifferent.
BAFF and APRIL Heteromers Are Differentially Inhibited by
BAFF and APRIL Antagonist Drugs—Belimumab is an anti-
BAFF antibody approved for the treatment of systemic lupus
erythematosus, and atacicept is a TACI:Fc fusion protein cur-
rently in a phase II clinical trial for the same disease. The ability
of these agents to inhibit BAFF-APRIL heteromers of defined
stoichiometry was investigated. At a few-fold mass excess over
the ligand, atacicept blocked not only BAFF andAPRIL but also
both types of heteromers (BAA and ABB) (Fig. 6). In contrast,
belimumab efficiently inhibited Fc-BAFF and Fc-BBB but had
very little to no activity on Fc-BBA, Fc-BAA, Fc-APRIL, and
Fc-AAA (Fig. 6). Thus, the specificity of belimumab is limited to
trimeric BAFF, whereas atacicept neutralizes BAFF and APRIL
trimers and all heteromeric configurations thereof.
Activity of Single-chain BAFF and BAFF-APRIL Heteromers
on Primary B Cells in Vivo—Although assays performed in the
first part of this study arewell defined from amolecular point of
view and informative regarding receptor binding specificity
of BAFF-APRIL heteromers, they do not address the capacity of
heteromers to activate full-length receptors expressed at
endogenous levels in a natural environment. To determine in
particular whether the weak binding of ABB to BAFFR is phys-
iologically relevant, Fc-tagged single-chain ligands were ad-
ministered to BAFF-KO mice. Indeed recombinant BAFF can
rescue a functionally mature B cell compartment in these mice,
at least to some extent (20, 43). In BAFF-KO mice, CD93-pos-
itive immature B cells are normal, but there are only few CD93-
negative mature B cells in the spleen and few mature B cells in
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lymph nodes (Fig. 7). As observed previously for Fc-BAFF,
administration of Fc-BBB at 1.5mg/kg for 2weeks to BAFF-KO
mice rescued both mature splenic and lymph node B cells (Fig.
7) (43). Fc-ABB was less efficient than Fc-BBB in this respect,
but nevertheless it significantly increased the number ofmature
splenic B cells. There was also a trend for increased lymph node
B cells in response to Fc-ABB, which did not reach statistical
significance (Fig. 7). Finally, as anticipated, Fc-BAA and Fc-
APRIL that do not bind to BAFFRhad no effect onmature B cell
populations (Fig. 7). Taken together, these results indicate that
BAFF-rich heteromers, but not APRIL-rich ones, have the
potential to functionally stimulate BAFFR in primary B cells in
vivo and to allow B cell maturation.
Discussion
The trimeric nature of both BAFF andAPRILmakes the pro-
duction and characterization of heteromers thereof a challeng-
ing issue, first to separate heteromers from homotrimers and
then to resolve heteromers of different compositions. Although
this is possible and has already been done for lymphotoxins (44)
and for the APRIL2BAFF1 heteromer (18), it is difficult to
exclude that exchanges of protomers at equilibrium might
restore a proportion of homotrimers in a purified heteromer. In
this regard, the strategy of expressing TNF family ligands as
single-chain proteins, which was initially developed to specifi-
cally introduce mutations in one but not all subunits of TNF
(45), has two undeniable advantages as follows: the generation
of heteromers with defined stoichiometry, and a guarantee
against exchanges of subunits. The size of FLAG-tagged and
untagged heteromers and the structure of ABB undoubtedly
confirmed that these constructs really formed heteromers.
Interestingly, interfaces between adjacent BAFF-BAFF, APRIL-
APRIL, BAFF-APRIL, or APRIL-BAFF subunits are virtually
identical in the central region of the interaction, and they often
involve similar residues in the peripheral part of the interaction
(Fig. 3C). A potential concern with single-chain ligands is the
FIGURE 4. Receptor binding specificity of BAFF-APRIL heteromers. A, binding of titrated amount of FLAG-tagged single-chain BAFF-APRIL heteromers to
the indicated immobilized receptors-Fc was monitored in an ELISA-based assay. B, binding of a constant, nonsaturating amount of FLAG-BAFF tomBAFFR-Fc
or BCMA-Fc was monitored in an ELISA-based assay. Before the addition of FLAG-BAFF, coated receptor Fcs were preincubated with titrated amounts of the
indicated untagged single-chain BAFF-APRIL heteromers that served as competitors for FLAG-BAFF.C, 293T cellswere co-transfectedwith plasmids coding for
the following: (a) the extracellular domain of hBAFFR fused to the C-terminal GPI addition signal of TRAILR3, and (b) EGFP as a fluorescent tracer. These cells
were stained with the indicated FLAG-tagged single-chain BAFF-APRIL heteromers (at 1 g/staining  40 g/ml). FACS scattergrams show the binding of
ligands (y axis) as a function of EGFP expression (which itself is proportional to BAFFR-GPI). Both axes show fluorescence intensities (from 100 to 104 arbitrary
units) on a log scale. The gate shows the population of cells with intermediate EGFP expression that was selected to quantifymean fluorescence intensity inD.
D, mean fluorescence intensity (MFI) of the binding of titrated amounts of the indicated single-chain FLAG-tagged heteromers to 293T cells expressing
hBAFFR-GPI, BCMA-GPI, TACI-GPI orno transfected receptor (Mock). Experimentwasperformedasdescribed inC. Experiments shown inA–Dare representative
of at least two with similar results.
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C-terminal amino acid, which in most TNF family ligands is
part of-sheet H and intimately involved in the structure of the
monomer (39), and it is appropriate to wonder whether the
addition of a linker at the C terminus of BAFF or APRIL affects
structure and activity of these ligands. Single-chain ligands of
lymphotoxins  and  were not only competent to bind recep-
tors (Fig. 1) (35) but also recapitulated known receptor-binding
specificities for these ligands (Fig. 1) (30, 34). Similarly, single-
chain heteromers of BAFF and APRIL retained receptor bind-
ing activity, and there were no noticeable differences in con-
structs when the single copies of BAFF or APRILwere placed in
position 1 or 2 (i.e.with a linker at theC terminus) or in position
3 (i.e. with a natural C terminus). In addition, there was no
evidence in the crystal structure of ABB that these short linkers
would perturb the structure of BAFF or APRIL in any way.
Taken together, these observations suggest that single-chain
heteromers provide a valid representation of “classical” homo-
or heterotrimers, at least for lymphotoxins and for BAFF and
APRIL.
It is worth mentioning that although LT is usually reported
to be active as heteromer with LT (34), it was also shown to
bind LTR on its own (46). In line with this later observation,
single-chain LT bound LTR with the same specificity as
LT12. The TNF ligand LIGHT binds to LTR and HVEM,
hence it will be interesting to test whether single-chain LT
interacts with receptors of the immediate TNF network
(TNFR1, TNFR2, HVEM, DcR3, LTR, and Fas).
A previously characterized APRIL2BAFF1 heteromer acti-
vated TACI as efficiently as APRIL in an NF-B reporter assay,
was less potent than either BAFF or APRIL taken alone in B cell
proliferation assays, and could be inhibited by BCMA-Fc and
TACI-Fc but not BAFFR-Fc (18). Our data are in linewith these
findings and extend them to APRIL1BAFF2. Briefly, BAA has a
similar receptor-binding specificity as AAA, whereas ABB
resembles BBB, except for a weaker binding to BAFFR. BAFF
has a weaker affinity for BCMA than APRIL (reviewed in Ref.
47), and here we find that ABB is also a weaker binder and
activator of BCMA than BAA. The difference is especially
FIGURE 5. Activity of BAFF-APRIL heteromers on BAFFR-, BCMA-, and TACI-specific reporter cell lines. Clones of Jurkat cells stably transduced with the
chimeric receptors hBAFFR:Fas, hBCMA:Fas, or hTACI:Fas were exposed to titrated amounts of the indicated single-chain BAFF-APRIL heteromers which, upon
binding, can activate the surrogate intracellular Fas apoptotic pathway that leads to cell death. A, effect of FLAG-tagged single-chain ligands cross-linkedwith
a fixed amount of anti-FLAG antibody on the indicated reporter cell lines. B, same as A, but with Fc-tagged single-chain ligands in the absence of cross-linkers.
C, same as A, but with untagged single-chain heteromers (and FLAG-BBB without anti-FLAG), all in the absence of cross-linker. Data shown in A–C are
representative of at least two experiments with comparable results.
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marked for uncross-linked heteromers, but it is attenuated in
the multimerized Fc-fusion constructs. Whether BAFF-APRIL
heteromers exist only as soluble trimeric molecules in vivo
and/or whether they are also multimerized, for example if they
exist in membrane-bound forms, remains to be investigated.
In contrast, the binding and activity of BAA and ABB on
TACIweremore comparable. ABBwas severely impaired com-
pared with BBB in all BAFFR binding and BAFFR activation
assays, yet they always retained some binding and functional
activity on BAFFR, including signaling in primarymouse B cells
in vivo. The only test system in which ABB showed no activity
was in a BAFF-BAFFR competition assay. This same ABB pro-
tein retained activity in a similar assay analyzing competition
with the BAFF-BCMA interaction (Fig. 4B). This indicates
that ABB has a lower affinity or avidity than BAFF for
BAFFR, a conclusion re-enforced by the examination of the
ABB crystal structure that suggests impaired binding to
BAFFR. Therefore, a direct consequence of BAFF incorpo-
ration into heteromers is to strongly reduce (ABB) or even
abrogate (BAA) its ability to activate BAFFR. Heteromers
can account for a fair proportion of circulating BAFF in
patient sera and may therefore control levels of BAFFR stim-
ulating activity (one study found 0% heteromer in six con-
trols, and 4–87% (average 32%) in 15 patients (19); a second
study reported heteromers in 7/89 controls and 24/89
patients with systemic lupus erythematosus, with heteromer
concentrations usually lower than those of BAFF, although
some subjects had heteromers but undetectable BAFF (48)).
What about stimulation of BCMA and TACI by heteromers?
It is predicted that the binding of BAFF, APRIL, or BAFF-
APRIL heteromers to TACI will be similar. However, binding to
and activation of TACI are distinct events in which ligand olig-
omerization (e.g. BAFF 60-mers or cross-linked APRIL) seems
indispensable for TACI activation, at least in primary mouse B
lymphocytes (20) and possible in humanmonocytes (49). Thus,
beyond the ability of heteromers to bind to TACI, their ability
to stimulate this receptor might well be determined by their
capacity or incapacity to oligomerize. Whether endogenous
heteromers can oligomerize via the Flap region that is present
in BAFF only or via the proteoglycan-binding region that is
present in APRIL only is presently an unresolved question. For
BCMA, so little is currently known about its activation require-
ments that it is difficult to speculatewhether heteromerswill be
worse, equal, or better ligands than BAFF or APRIL.
FIGURE 6.Sensitivity of BAFF-APRIL heteromers of defined stoichiometries toBAFF andAPRIL inhibitors.BCMA:Fas and TACI:Fas reporter cell lineswere
treatedwith lethal doses (except for BBA, BAB, andABBonBCMA:Fas cells; dose inng/ml indicated inparentheses) of the indicated single-chain or conventional
BAFF and/or APRIL-containing ligands, in the presence or absence of titrated amounts of hTACI-Ig (atacicept) or anti-BAFFmAb (belimumab). Cell survival was
monitored with a cell viability assay. One experiment out of two with similar results is shown.
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We therefore propose two main hypotheses for the physio-
logical role of BAFF-APRIL heteromers as follows: (a) they act
as partial functional antagonists of both BAFF and APRIL and
down-modulate responses of these ligands on all cells known to
respond to BAFF and/or APRIL; (b) conversely, they act as
dominant negative inhibitors of BAFF signaling on BAFFR,
which will affect naive mature B cells. However, they can signal
via TACI and BCMA and will therefore support activated and
differentiated B cells such as plasmablasts and plasma cells. In
the later scenario, heteromers favor antigen-experiencedB cells
at the expense of naive ones.
Some hints to distinguish between one or the other hypoth-
esis may come from clinical trials comparing single BAFF
antagonists (belimumab/Benlysta) to dual BAFF- and APRIL-
blocking reagents (i.e. atacicept, which is a TACI-Ig fusion pro-
tein) (10). Indeed, we show here that ABB and BAAheteromers
are efficiently blocked by atacicept but not belimumab. If
endogenous heteromers support survival of plasmablasts and
plasma cells in vivo, then atacicept but not belimumab is
expected to affect these cell types; the interpretation will, how-
ever, be complicated by the fact that atacicept also inhibits
APRIL; the development of specific heteromer antagonists that
inhibit neither BAFF nor APRIL will probably be necessary to
definitively address the role of heteromers in health and dis-
ease. From a mechanistic point of view, the inability of beli-
mumab to interferewithABB is surprising, as onewould expect
that it should recognize at least the BB interface. A rational
explanation for why belimumab fails to inhibit ABB will prob-
ably require crystallization of the belimumab-BAFF complex.
The Flap is a long loop between-sheetsD and E (specifically
present in BAFF but no other TNF family ligand) that mediates
contact between BAFF trimers and is responsible for the for-
mation of BAFF 60-mers (14, 50). Interestingly, the arrange-
ment of the Flap was not only well resolved in structures of
BAFF 60-mers but also in crystals of BAFF 3-mers (Fig. 3D) (13,
14, 36–38, 41), suggesting that it may fulfill functions beyond
the mere formation of 60-mers.4 In ABB, the Flap of only one
BAFF subunit was similar to that found in BAFF 60-mers, and
the second one was differently rearranged, suggesting that a
single Flap-Flap interactionmight take place betweenABB het-
eromers, although this will be difficult to demonstrate experi-
mentally in solution. Indeed, under conditions where BAFF oli-
gomerizes into 60-mers, 3- and 60-mers are visible in the
absence of any defined oligomers of intermediate sizes (14, 50,
51). The Flap region of the C-terminal BAFF subunit of ABB
adopted a different, yet well defined conformation that was
never observed before (Fig. 3D). In the structure, this Flap is
also involved in the interaction with an adjacent ABB, but
whether and how this affects ABB functionality will require
further investigations.
In conclusion, the single-chain ligand technology was suc-
cessful for studying the properties of BAFF-APRIL heteromers
of defined stoichiometry and provided useful tools for the char-
acterization of BAFF and/or APRIL inhibitors. In the future,
these reagents will also help to determine whether reagents
4 M. Vigolo and P. Schneider, unpublished observations.
FIGURE 7. Effect of single-chain BAFF-APRIL heteromers in Baff-deficientmice. BAFF-KOmice were treated four times over 2 weeks with 1.5mg/kg of the
indicated Fc-tagged conventional or single-chain ligands orwith buffer (PBS).Micewere sacrificed 4days after the last injection. Spleens and lymphnodes (LN)
were analyzed by FACS for the presence of T cells (T) (CD3), B cells (B) (CD19), immature splenic B cells (imB) (CD19CD93), andmature splenic B cells (mB)
(CD19CD93). Untreated wild type (WT) mice were included as controls. A, representative scattergrams of splenic and lymph node cells from mice treated
with the indicated Fc ligands. B, ratio ofmature B cells to T cells in spleens ofmice that received the indicated treatments. C, ratio of B to T cells in lymph nodes
of mice that received the indicated treatments.D, results of statistical one-way analyses of variance (ANOVA) with Bonferroni’s post test multiple comparisons
for data shown in B and C. ns, not significant; *, p 0.05; **, p 0.01; ***, p 0.001. Experiment was performed once with three mice per condition (six mice
for WT and six mice for PBS-treated BAFF-KO).
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used to quantify BAFF or APRIL cross-react with the different
forms of BAFF-APRIL heteromers.
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